` 300255 (Hebei Changshan Biochemical Pharmaceutical Co Ltd) vs Shanghai Composite Comparison - Alpha Spread

300255
vs
S
Shanghai Composite

Over the past 12 months, Hebei Changshan Biochemical Pharmaceutical Co Ltd has significantly outperformed Shanghai Composite, delivering a return of +90% compared to the Shanghai Composite's +24% growth.

Stocks Performance
300255 vs Shanghai Composite

Loading
300255
Shanghai Composite
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
300255 vs Shanghai Composite

Loading
300255
Shanghai Composite
Difference
www.alphaspread.com

Performance By Year
300255 vs Shanghai Composite

Loading
300255
Shanghai Composite
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Hebei Changshan Biochemical Pharmaceutical Co Ltd vs Peers

Shanghai Composite
300255
JEF
JNJ
4312
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Hebei Changshan Biochemical Pharmaceutical Co Ltd
Glance View

Market Cap
35B CNY
Industry
Pharmaceuticals

Hebei Changshan Biochemical Pharmaceutical Co., Ltd. operates as a key player in the global pharmaceutical industry, with a focused mission of advancing healthcare through innovative biochemical products. Founded in the heartland of China's Hebei province, the company has carved out a niche for itself by specializing in the production of heparin, a critical anticoagulant used in preventing and treating blood clots. Through state-of-the-art biotechnology and substantial R&D investments, Changshan Biochemical has mastered the complex extraction and refining processes that transform raw materials, often sourced from porcine intestinal mucosa, into these essential, life-saving pharmaceuticals. This scientific prowess is not just an end in itself; it represents the backbone of the company's business model, driving both their product portfolio and revenue streams. The company's success is intricately tied to its ability to integrate vertically and scale efficiently, which enhances operational agility and cost management. Such vertical integration involves controlling multiple stages of production—from raw material sourcing and synthesis to finished product distribution—ensuring consistent quality and supply. Moreover, Hebei Changshan's strategic emphasis on innovation allows it to develop new formulations and applications for its biochemical products, expanding its market reach both domestically and internationally. Revenue generation is largely derived from hospital sales, direct pharmaceuticals sales, and partnerships with other biotech firms. By leveraging its biochemical expertise and maintaining robust industry relationships, Changshan Biochemical not only secures its financial performance but also positions itself as a dependable partner in the global healthcare supply chain.

Intrinsic Value
3.95 CNY
Overvaluation 90%
Intrinsic Value
Price ¥38.04
Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett